Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States

被引：0
|
作者：
Weiting Liao
Wanting Lei
Mingyang Feng
Yang Yang
Qiuji Wu
Kexun Zhou
Liangliang Bai
Feng Wen
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Cost-effectiveness; Anti-angiogenesis; Immunotherapy; Cabozantinib; Nivolumab; Renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5662 / 5670
页数：8
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
    Chandler, Conor
    Burnett, Heather
    Schaible, Kassandra
    Senthil, Vishnu
    Kato, Masafumi
    Miura, Yuji
    Osawa, Takahiro
    Uemura, Hiroji
    Kuwabara, Hiroyo
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1009 - 1018
  • [22] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [23] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] CaboCombo: a prospective, phase IV study of first-line cabozantinib plus nivolumab for advanced renal cell carcinoma
    Barthelemy, Philippe
    Dutailly, Pascale
    Qvick, Bryan
    Perrot, Valerie
    Verzoni, Elena
    FUTURE ONCOLOGY, 2024, 20 (13) : 811 - 819
  • [25] COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
    Skentzou, E.
    Meng, J.
    Lister, J.
    Gray, L.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [26] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Jun Chen
    Gaoyun Hu
    Zhuo Chen
    Xiaomin Wan
    Chongqing Tan
    Xiaohui Zeng
    Zeneng Cheng
    Clinical Drug Investigation, 2019, 39 : 931 - 938
  • [27] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [28] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Chen, Jun
    Hu, Gaoyun
    Chen, Zhuo
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    Cheng, Zeneng
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 931 - 938
  • [29] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [30] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
12345